Review of the Proposed Generic Drug and Biosimilars User Fees and Further Examination of Drug Shortages

Panel I 

Dr. Janet Woodcock


• Director
Center for Drug Evaluation and Research

• Food and Drug Administration

• Witness Testimony (Truth in Testimony)

Panel II



Ms. Heather Bresch


• CEO
Mylan, Inc.

• Witness Testimony (Truth in Testimony)


Mr. David Gaugh


• Vice President, Regulatory Sciences
• 
Generic Pharmaceutical Association
• 
Witness Testimony (Truth in Testimony)



Mr. Bill Greene, Pharm. D., BCPS, FASHP

• 
Chief Pharmaceutical Officer

• Pharmaceutical Services

• Member, Pharmaceutical Sciences

• St. Jude Children’s Research Hospital

• Witness Testimony (Truth in Testimony)